Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Hematologic Diseases 3Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Preleukemia 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × lintuzumab × Clear all
NCT00528333 2015-01-07

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Seagen Inc.

Phase 2 Completed
211 enrolled
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Acute

NCT00283114 2014-12-18

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Seagen Inc.

Phase 1 Completed
82 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00502112 2011-10-12

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Seagen Inc.

Phase 1 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡